Artiva Biotherapeutics, Inc. Common Stock
ARTV
About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Employees: 105
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
9% less funds holding
Funds holding: 53 [Q1] → 48 (-5) [Q2]
9.91% less ownership
Funds ownership: 85.88% [Q1] → 75.97% (-9.91%) [Q2]
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
55% less capital invested
Capital invested by funds: $62.8M [Q1] → $27.9M (-$34.8M) [Q2]
Financial journalist opinion
